Cargando…

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis

Targeted therapies within the RAS/RAF/MEK/ERK signalling axis become increasingly popular, yet cross-talk and feedbacks in the signalling network lead to unexpected effects. Here we look systematically into how inhibiting RAF and MEK with clinically relevant inhibitors result in changes in PI3K/AKT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fritsche-Guenther, Raphaela, Witzel, Franziska, Kempa, Stefan, Brummer, Tilman, Sers, Christine, Blüthgen, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884967/ https://www.ncbi.nlm.nih.gov/pubmed/26799289 http://dx.doi.org/10.18632/oncotarget.6959

Ejemplares similares

Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2011)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
por: Nolan, Aoife A., et al.
Publicado: (2021)

CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways
por: Al Shahrani, Mesfer, et al.
Publicado: (2022)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Network quantification of EGFR signaling unveils potential for targeted combination therapy
por: Klinger, Bertram, et al.
Publicado: (2013)

Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
por: Wang, Fei, et al.
Publicado: (2022)

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
por: Cai, Wenpeng, et al.
Publicado: (2023)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

An engineered protein antagonist of K-Ras/B-Raf interaction
por: Kauke, Monique J., et al.
Publicado: (2017)

Intra-Cellular Calcium Signaling Pathways (PKC, RAS/RAF/MAPK, PI3K) in Lamina Cribrosa Cells in Glaucoma
por: Irnaten, Mustapha, et al.
Publicado: (2020)

Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
por: Travers, Timothy, et al.
Publicado: (2018)

Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation
por: Cookis, Trinity, et al.
Publicado: (2021)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Role of autophagy in K-RAS- and B-RAF-driven lung cancers
por: White, Eileen
Publicado: (2014)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Tran, Timothy H., et al.
Publicado: (2021)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis
por: Houben, Roland, et al.
Publicado: (2004)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway
por: Zhao, Jingtong, et al.
Publicado: (2022)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase
por: Rohrer, Lino, et al.
Publicado: (2023)

Arabidopsis Raf-Like Kinase Raf10 Is a Regulatory Component of Core ABA Signaling
por: Nguyen, Quy Thi Cam, et al.
Publicado: (2019)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression
por: Götz, Rudolf
Publicado: (2008)

Ras and Calcium Signaling Pathways Converge at Raf1 via the Shoc2 Scaffold Protein
por: Yoshiki, Sayaka, et al.
Publicado: (2010)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
por: García-Echeverría, Carlos
Publicado: (2008)

Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma
por: HOU, WENMIN, et al.
Publicado: (2014)

Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K
por: Pallegar, Nikitha K., et al.
Publicado: (2015)

Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways
por: Li, Yun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8vn30od6ja3caeqpk70uqqu2e0